Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition

被引：267

作者：

Alvarez-Fernandez, Monica ^{[1
,2
]}

Malumbres, Marcos ^{[1
]}

机构：

[1] Spanish Natl Canc Res Ctr CNIO, Cell Div & Canc Grp, Melchor Fernandez Almagro 3, Madrid 28029, Spain

[2] Inst Invest Sanitaria Principado Asturias ISPA, Ave Roma S-N, Oviedo 33011, Spain

来源：

CANCER CELL | 2020年 / 37卷 / 04期

关键词：

CYCLIN-DEPENDENT KINASES; CELL LUNG-CANCER; BREAST-CANCER; TYROSINE PHOSPHORYLATION; THERAPEUTIC STRATEGY; INDEPENDENT FUNCTION; CDK6; INHIBITOR; OVARIAN-CANCER; PHASE-II; TUMOR;

D O I：

10.1016/j.ccell.2020.03.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in patients with advanced hormone-positive breast cancer. The efficacy of this strategy is, however, limited by innate or acquired resistance mechanisms and its application to other tumor types is still uncertain. Here, through an integrative analysis of sensitivity and resistance mechanisms, we discuss the use of CDK4/6 inhibitors in combination with available targeted therapies, immunotherapy, or classical chemotherapy with the aim of improving future therapeutic uses of CDK4/6 inhibition in a variety of cancers.

引用

页码：514 / 529

页数：16

共 140 条

[1] Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma [J].

AbuHammad, Shatha ;

Cullinane, Carleen ;

Martin, Claire ;

Bacolas, Zoe ;

Ward, Teresa ;

Chen, Huiqin ;

Slater, Alison ;

Ardley, Kerry ;

Kirby, Laura ;

Chan, Keefe T. ;

Brajanovski, Natalie ;

Smith, Lorey K. ;

Rao, Aparna D. ;

Lelliott, Emily J. ;

Kleinschmidt, Margarete ;

Vergara, Ismael A. ;

Papenfuss, Anthony T. ;

Lau, Peter ;

Ghosh, Prerana ;

Haupt, Sue ;

Haupt, Ygal ;

Sanij, Elaine ;

Poortinga, Gretchen ;

Pearson, Richard B. ;

Falk, Hendrik ;

Curtis, David J. ;

Stupple, Paul ;

Devlin, Mark ;

Street, Ian ;

Davies, Michael A. ;

McArthur, Grant A. ;

Sheppard, Karen E. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (36) :17990-18000

[2] Cdc2-cyclin E complexes regulate the G1/S phase transition [J].

Aleem, E ;

Kiyokawa, H ;

Kaldis, P .

NATURE CELL BIOLOGY, 2005, 7 (08) :831-U93

[3] A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells [J].

Anders, Lars ;

Ke, Nan ;

Hydbring, Per ;

Choi, Yoon J. ;

Widlund, Hans R. ;

Chick, Joel M. ;

Zhai, Huili ;

Vidal, Marc ;

Gygi, Stephen P. ;

Braun, Pascal ;

Sicinski, Piotr .

CANCER CELL, 2011, 20 (05) :620-634

[4] The history and future of targeting cyclin-dependent kinases in cancer therapy [J].

Asghar, Uzma ;

Witkiewicz, Agnieszka K. ;

Turner, Nicholas C. ;

Knudsen, Erik S. .

NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (02) :130-146

[5]

Behenna D.C., 2018, USA Patent Application Publication, Patent No. [US 2018/0044344 A1, CDK2/4/6]

[6] CDK6 Antagonizes p53-Induced Responses during Tumorigenesis [J].

Bellutti, Florian ;

Tigan, Anca-Sarmiza ;

Nebenfuehr, Sofie ;

Dolezal, Marlies ;

Zojer, Markus ;

Grausenburger, Reinhard ;

Hartenberger, Svenja ;

Kollmann, Sebastian ;

Doma, Eszter ;

Prchal-Murphy, Michaela ;

Uras, Iris Z. ;

Hoellein, Alexander ;

Neuberg, Donna S. ;

Ebert, Benjamin L. ;

Ringler, Anna ;

Mueller, Andre C. ;

Loizou, Joanna I. ;

Hinds, Philip W. ;

Vogl, Claus ;

Heller, Gerwin ;

Kubicek, Stefan ;

Zuber, Johannes ;

Malumbres, Marcos ;

Farlik, Matthias ;

Villunger, Andreas ;

Kollmann, Karoline ;

Sexl, Veronika .

CANCER DISCOVERY, 2018, 8 (07) :884-897

[7] Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors [J].

Bisi, John E. ;

Sorrentino, Jessica A. ;

Jordan, Jamie L. ;

Darr, David D. ;

Roberts, Patrick J. ;

Tavares, Francis X. ;

Strum, Jay C. .

ONCOTARGET, 2017, 8 (26) :42343-42358

[8] Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression [J].

Bisi, John E. ;

Sorrentino, Jessica A. ;

Roberts, Patrick J. ;

Tavares, Francis X. ;

Strum, Jay C. .

MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) :783-793

[9] Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells [J].

Caldon, C. Elizabeth ;

Sergio, C. Marcelo ;

Kang, Jian ;

Muthukaruppan, Anita ;

Boersma, Marijke N. ;

Stone, Andrew ;

Barraclough, Jane ;

Lee, Christine S. ;

Black, Michael A. ;

Miller, Lance D. ;

Gee, Julia M. ;

Nicholson, Rob I. ;

Sutherland, Robert L. ;

Print, Cristin G. ;

Musgrove, Elizabeth A. .

MOLECULAR CANCER THERAPEUTICS, 2012, 11 (07) :1488-1499

[10] Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer [J].

Cao, Joan ;

Zhu, Zhou ;

Wang, Hui ;

Nichols, Timothy C. ;

Lui, Goldie Y. L. ;

Deng, Shibing ;

Rejto, Paul A. ;

VanArsdale, Todd ;

Hardwick, James S. ;

Weinrich, Scott L. ;

Wei, Ping .

ONCOGENE, 2019, 38 (21) :4125-4141

← 1 2 3 4 5 6 7 8 9 10 →